Derivatives of 3-isoxazolecarboxylic acid esters - a potent and selective compound class against replicating and nonreplicating Mycobacterium tuberculosis

Current Topics in Medicinal Chemistry

Volumn 12, Issue 7, 2012, Pages 729-734

  Lilienkampf, Annamaria ^a,c   Pieroni, Marco ^a,d   Franzblau, Scott G ^a   Bishai, William R ^b   Kozikowski, Alan P ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF PARMA   (Italy)

Author keywords

Drug resistance; Inhibition; Isoxazole; Mycobacterium; Persistence; Quinoline; Tuberculosis

Indexed keywords

3 ISOXAZOLECARBOXYLIC ACID ESTER; ISONIAZID; MEFLOQUINE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; CELL MEMBRANE PERMEABILITY; CYTOTOXICITY; HIGH THROUGHPUT SCREENING; HUMAN; HYDROPHILICITY; IC 50; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; STRUCTURE ACTIVITY RELATION; VERO CELL;

ANIMALS; ANTITUBERCULAR AGENTS; ESTERS; HUMANS; ISOXAZOLES; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84860299852     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612799984544     Document Type: Article

References (23)

1. WHO Global tuberculosis control Report 2011. Available at: http://www.who.int/tb/publications/global_report/2011/gtbr11_executive_summary.pdf (accessed January 2012).
2. Van den Boogaard, J.; Kibiki, G. S.; Kisanga, E. R.; Boeree, M. J.; Aarnoutse, R. E. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob. Agents Chemother., 2009, 53, 849-862.
3. http://www.who.int/tb/dots/whatisdots/en/index.html (accessed February 2009).
4. Mitchison D. A. The search for new sterilizing anti-tuberculosis drugs. Front Biosci., 2004, 9, 1059-1072.
5. Boshoff, H. I. M.; Barry, C. E. III. Tuberculosis metabolism and respiration in the absence of growth. Nat. Rev. Microbiol., 2005, 3, 70-80.
6. Wayne, L. G.; Sohaskey, C. D. Nonreplicating persistence of mycobacterium tuberculosis. Annu. Rev. Microbiol., 2001, 55, 139-163.
7. Rae, J. M.; Johnson, M. D.; Lippman, M. E.; Flockhart, D. A. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J. Pharmacol. Exp. Ther., 2001, 299, 849-857.
8. Jassal, M.; Bishai, W. R. Extensively drug-resistant tuberculosis. Lancet Infect. Dis., 2009, 9, 19-30.
9. Andries, K.; Verhasselt, P.; Guillemont, J.; Goehlmann, H. W. H.; Neefs, J.-M.; Winkler, H.; Van Gestel, J.; Timmerman, P.; Zhu, M.; Lee, E.; Williams, P.; de Chaffoy, D.; Huitric, E.; Hoffner, S.; Cambau, E.; Truffot-Pernot, C.; Lounis, N.; Jarlier, V. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005, 307, 223-227.
10. Stover, C. K.; Warrener, P.; Van Devanter, D. R.; Sherman, D. R.; Arain, T. M.; Langhorne, M. H.; Anderson, S. W.; Towell, J. A.; Yuan, Y.; McMurray, D. N.; Krelswirth, B. N.; Barry, C. E.; Baker, W. R. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 2000, 405, 962-966.
11. Matsumoto, M.; Hashizume, H.; Tomishige, T.; Kawasaki, M.; Tsubouchi, H.; Sasaki, H.; Shimokawa, Y.; Komatsu, M. OPC- 67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med., 2006, 3, 2131-2144.
12. Rivers, E. C.; Mancera, R. L. New anti-tuberculosis drugs in clinical trials with novel mechanisms of action. Drug Discov. Today, 2008, 13, 1090-1098.
13. Jayaprakash, S.; Iso, Y.; Wan, B.; Franzblau, S. G.; Kozikowski, A. P. Design, synthesis, and SAR studies of mefloquine-based ligands as potential antituberculosis agents. ChemMedChem, 2006, 1, 593-596.
14. In addition, Bermudez and co-workers have mentioned Mefloquine to have in vitro activity against Mtb; however, no data was reported. Danelishvili, L.; Wu, M.; Young, L. S.; Bermudez, L. E. Genomic approach to identifying the putative target of and mechanisms of resistance to mefloquine in Mycobacteria. Antimicrob. Agents Chemother., 2005, 49, 3707-3714.
15. Mao, J.; Wang, Y.; Wan, B.; Kozikowski, A. P.; Franzblau, S. G. Design, synthesis, and pharmacological evaluation of mefloquinebased ligands as novel antituberculosis agents. Chem. Med. Chem., 2007, 2, 1624-1630.
16. Huang, Q.; Mao, J.; Wan, B.; Wang, Y.; Brun, R.; Franzblau, S. G.; Kozikowski, A. P. Searching for new cures for tuberculosis - design, synthesis, and biological evaluation of 2-methylbenzothiazoles, J. Med. Chem., 2009, 52, 6757-6767.
17. Mao, J.; Wan, B.; Wang, Y.; Franzblau, S. G.; Kozikowski, A. P. HTS chemical hybridization, and drug design identify a chemically unique antituberculosis agents coupling serendipity and rational approaches to drug discovery. Chem. Med. Chem., 2007, 2, 811-813.
18. Lilienkampf, A.; Mao, J.; Wan, B.; Wang, Y.; Franzblau, S. G.; Kozikowski, A. P. Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis. J. Med. Chem., 2009, 52, 2109-2118.
19. Mao, J.; Yuan, H.; Wang, Y.; Wan, B.; Pieroni, M.; Huang, Q.; van Breemen, R. B.; Kozikowski, A. P.; Franzblau, S. G. From Serendipity to Rational Antituberculosis Drug Discovery of Mefloquine- Isoxazole Carboxylic Acid Esters. J. Med. Chem., 2009, 52, 6966-6978.
20. Pieroni, M.; Lilienkampf, A.; Wan, B.; Wang, Y.; Franzblau, S.G.; Kozikowski A. P. Synthesis, biological evaluation, and structureactivity relationships for 5-[(E)-2-Arylethenyl]-3-isoxazolecarboxylic acid alkyl ester derivatives as valuable antitubercular chemotypes. J. Med. Chem. 2009, 52, 6287-6296.
21. Lilienkampf, A.; Pieroni, M.; Wan, B.; Wang, Y.; Franzblau, S. G.; Kozikowski A. P. Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of mycobacterium tuberculosis - a potent and selective series for further drug development. J. Med. Chem., 2010, 53, 678-688.
22. Mao, J.; Yuan, H.; Wang, Y.; Wan, B.; Pak, D.; He, R.; Franzblau, S. G. Synthesis and antituberculosis activity of novel mefloquineisoxazole carboxylic esters as prodrugs. Bioorg. Med. Chem. Lett., 2010, 20, 1263-1268.
23. Wade, M. M.; Zhang, Y. Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro. J. Antimicrob. Chemother., 2006, 58, 936-941.